December 8, 2022

Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTH...
Read more
December 7, 2022

Oncopeptides provides update on Pepaxto US marketing authorization

STOCKHOLM — December 07, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hemato...
Read more
December 5, 2022

Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis

First randomized clinical investigation with a digital therapy (DTx) to address the psychological symptom burden in pulmonary fibrosis (PF) patientsFirst patient enrolled in US pi...
Read more
November 30, 2022

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life REDWOOD CITY...
Read more
November 25, 2022

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank

STOCKHOLM — November 25, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...
Read more
November 14, 2022

Priothera – Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy

Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell transplantation (HCT) patients Mocravimod significantly reduced circulating lymphocyte numbers and&n...
Read more
November 11, 2022

Oncopeptides’ Pepaxti has been granted marketing authorization in the UK

STOCKHOLM — November 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hema...
Read more
November 10, 2022

Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment Appointment of Saba Sile, M.D., as Vice President of Clinical Development SAN FRANCIS...
Read more
November 10, 2022

Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement

Hubro acquires the GM-CSF project from Targovax for a cash payment of NOK10mHubro will continue the development of GM-CSF as adjuvant for use with its pipeline of novel cancer vac...
Read more
November 9, 2022

Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing n...
Read more
Older news →